Clinical Research and Integrated Care for Post-Infection Long-Term Conditions

Keralty is an international integrated health group delivering care to 9 million patients with 27,000 professionals across Colombia, Peru, Mexico, and the United States, with strong expertise in primary care, chronic disease management, rehabilitation, and social care. Keralty has successfully participated in H2020 and Horizon Europe projects, contributing structured cohorts, clinical research capacity, and real-world implementation settings.

Keralty is well positioned to contribute to HORIZON-HLTH-2026-01-DISEASE-03, supporting the prevention, diagnosis, and management of post-infection long-term conditions across diverse populations. Keralty has cared for more than 5M COVID-19 patients in our specialized centres and continue to treat patients with post-COVID-19 condition. With the data gathered, we are willing to conduct clinical studies to improve the care of patients with long-covid and other long-term conditions. Through its healthcare network, Keralty can support:

• Access to large and heterogeneous patient populations, including individuals with post-infectious sequelae and multimorbidity

• Clinical and longitudinal studies, including early-stage clinical trials and real-world follow-up

• Integrated analysis of biological, clinical, behavioural, and socio-economic factors relevant to disease progression and recovery

• Implementation and evaluation of care pathways across primary, specialised, and community-based settings

Keralty has particular experience in managing chronic inflammatory conditions, functional impairment, mental health comorbidities, and rehabilitation needs, which are common in post-infection syndromes. Its integrated care model enables the testing of multidisciplinary and patient-centred interventions, including physical rehabilitation, psychological support, and digital disease management tools, with a strong focus on equity, sex and gender differences, and vulnerable populations.

In addition, BioKeralty Research Institute, part of Keralty Group’s R&D&I division, can act as a complementary research partner. BioKeralty brings expertise in chronic diseases, personalised medicine, digital health, data analytics, and translational research, supporting biomarker research, data harmonisation, and the application of FAIR data principles. BioKeralty also contributes strong capabilities in communication, dissemination, and exploitation, enhancing impact, stakeholder engagement, and policy relevance.

Together, Keralty and BioKeralty offer a robust combination of clinical research capacity, real-world cohorts, integrated care expertise, SSH-informed approaches, and experience in EU-funded collaborative projects. They are keen to collaborate with universities, research institutes, SMEs, public authorities, and patient organisations in consortia addressing post-infection long-term conditions, aiming to improve patient outcomes, reduce healthcare system burdens, and strengthen public health preparedness and resilience.